CN103599525A - Chelated calcium electuary - Google Patents
Chelated calcium electuary Download PDFInfo
- Publication number
- CN103599525A CN103599525A CN201310551948.1A CN201310551948A CN103599525A CN 103599525 A CN103599525 A CN 103599525A CN 201310551948 A CN201310551948 A CN 201310551948A CN 103599525 A CN103599525 A CN 103599525A
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- chelated calcium
- electuary
- bone
- calcium electuary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 12
- 239000011575 calcium Substances 0.000 title claims abstract description 12
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 5
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 5
- 239000011710 vitamin D Substances 0.000 claims abstract description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 5
- 229940046008 vitamin d Drugs 0.000 claims abstract description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 4
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000005018 casein Substances 0.000 abstract 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
- 235000021240 caseins Nutrition 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 description 16
- 206010017076 Fracture Diseases 0.000 description 6
- 208000008035 Back Pain Diseases 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019804 backache Diseases 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 206010016997 Forearm fracture Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 208000002103 Shoulder Fractures Diseases 0.000 description 1
- 206010072985 Spinal column fractures Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a chelated calcium electuary, which is mainly prepared from L-asparaginic acid chelated calcium, casein phosphopeptide and vitamin D.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of chelating calcium electuary.
Background technology
Osteoporosis is a kind of commonly encountered diseases and frequently-occurring disease, and it is seriously threatening middle-aged and elderly people, and especially postmenopausal women is healthy.The complication such as the fracture being caused by osteoporosis, have caused great misery to patient, return society and family and have brought heavy economy and living burden.According to reports, the probability that the osteoporotic women of generation occurred hip, spinal column, forearm or proximal humeral fracture in 10 years later in 50 years old is up to 45%; Be greater than 65 years old old man when unconscious falling, have 87% can cause osteoporotic fracture.China old people's absolute quantity accounts for No. 1 in the world, and along with the growth of growth in the living standard and population life, the aged sharply increases, and therefore, the diagnosis of osteoporosis and control thereof just seem very important.
Osteoporosis can be divided into three major types, and a class is primary osteoporosis, is a kind of physiological degeneration that must occur with advancing age.Equations of The Second Kind is secondary osteoporosis, and it is the osteoporosis of being brought out by some factors such as Other diseases or medicines.The 3rd class is idiopathic osteoporosis disease, is more common in teenager or the adult of 8～14 years old, mostly has family's heredity medical history, and women is more than male.The osteoporosis that gravid woman and women breast-feeding their children occur also can be listed idiopathic osteoporosis in, to cause people's attention.
The main clinical manifestation of osteoporosis and sign are: pain, height shortening, hunchback, fragility fractures and Respiratory Disturbances etc.
1) pain
Pain is the common sympton of osteoporosis, and its reason is mainly that bone resorption increases because bone conversion is high.In bone resorption process, bone trabecular destruction, disappearance, the destruction of subperiosteum cortical bone etc. all can cause general osteodynia, wherein common with lumbago and backache.Another causes that the major reason of pain is fracture.
2) height shortening, hunchback
In silent middle height, shortening or bow-backed, is one of important clinical sign occurring continue lumbago and backache after, and 5-20 centimetre of height shortening is not sometimes etc.
3) fragility fractures
In osteoporosis, skeleton fracture threshold reduces significantly, thereby just easily fractured by slight external force.
4) Respiratory Disturbances
Breast, compression fracture of lumbar vertebra due to serious osteoporosis, usually cause kyphosis, chest deformity, and thoracic cavity capacity obviously declines, and sometimes can cause the changes of function of a plurality of internal organs, and wherein the performance of respiratory system is particularly outstanding.
The final purpose of protect against osteoporosis is to reduce the generation of fracture.Adopt clinically and delay and reduce bone loss, strive for recapturing bone amount, increase bone strength and reach this object.The treatment measure of osteoporosis is divided into basic measure and two aspects of Drug therapy.In the measure of basis, bone health supplement are mainly calcium preparation and vitamin D; Drug therapy mainly comprises anti-bone resorption medicine, short bone formation medicine and other drug.
Summary of the invention
The object of the present invention is to provide a kind of chelating calcium electuary.
For achieving the above object, the present invention adopts the component of following weight ratio: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: chelating calcium electuary, its raw material and weight portion are: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
Claims (1)
1. chelating calcium electuary, is characterized in that, comprises the component of following weight ratio: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310551948.1A CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310551948.1A CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103599525A true CN103599525A (en) | 2014-02-26 |
Family
ID=50117831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310551948.1A Pending CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599525A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310024A (en) * | 2001-02-21 | 2001-08-29 | 深圳市海川实业股份有限公司 | Microencapsulated compound nutrient complementing agent |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103169092A (en) * | 2013-03-21 | 2013-06-26 | 翁国富 | L-asparaginic acid chelated calcium drinking water |
-
2013
- 2013-11-08 CN CN201310551948.1A patent/CN103599525A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310024A (en) * | 2001-02-21 | 2001-08-29 | 深圳市海川实业股份有限公司 | Microencapsulated compound nutrient complementing agent |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103169092A (en) * | 2013-03-21 | 2013-06-26 | 翁国富 | L-asparaginic acid chelated calcium drinking water |
Non-Patent Citations (1)
| Title |
|---|
| 国家食品药品监督管理总局: "给尔新冲剂（L-天门冬氨酸钙）", 《国家食品药品监督管理总局数据库》, 9 October 1999 (1999-10-09) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103584106A (en) | Composition capable of improving bone mineral density | |
| CN103599186A (en) | Compound lotus root starch preparation | |
| Chen et al. | Intrathoracic dislocation of the humeral head accompanied by polytrauma: How to treat it | |
| CN103610755A (en) | Granules for treating osteoporosis | |
| CN103565827A (en) | Resveratrol-containing tablets | |
| CN103599525A (en) | Chelated calcium electuary | |
| CN104587470B (en) | Pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of pharmaceutical composition | |
| Oliver et al. | Hip fracture | |
| CN103599521A (en) | Vitamin D complex granules | |
| CN103611152A (en) | Compound vitamin D electuary | |
| CN103565830A (en) | Composite calcium preparation | |
| CN103599524A (en) | Compound walnut powder solid preparation | |
| CN103599096A (en) | Resveratrol tablet | |
| CN110693035A (en) | Peptide-containing composition for osteoporosis people to eat and application thereof | |
| CN103610740A (en) | Calcium chelate | |
| CN103599168A (en) | Composition for enhancing bone density | |
| CN103599177A (en) | Composition for enhancing bone density | |
| CN103599174A (en) | Composition for improving bone mineral density | |
| CN103566355A (en) | Composite lotus root starch preparation | |
| CN103599176A (en) | Composition for enhancing bone density | |
| CN103585457B (en) | A kind of medicament for the treatment of fracture | |
| CN103585264A (en) | Preparation capable of increasing bone mineral density | |
| CN103735613A (en) | Preparation for increasing bone mineral density | |
| CN103623048A (en) | Preparation containing pueraria isoflavones | |
| CN103565930A (en) | Granule for increasing bone density |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140226 |